From hydration to lifesaving medications, IV delivery plays a critical role across care settings. Yet, despite its routine nature, IV therapy carries inherent risks—most notably infiltration and extravasation—that can lead to serious patient harm if not detected early.
Clinicians today rely on a set of well-established prevention techniques. Selecting the right vein, choosing the appropriate catheter size, and placing the line at the optimal time are all foundational steps. Add to those routine visual assessments—often performed hourly—and you have what is considered standard practice. These methods matter. They reduce risk. But they are not infallible.
The reality is this: a lot can happen in the 59 minutes between bedside checks.
IV complications don’t operate on a schedule. Infiltration and extravasation can begin subtly and progress rapidly, often without immediate visible signs. By the time swelling, redness, or patient discomfort becomes apparent, damage may already be well underway. For vulnerable populations—such as pediatric, geriatric, or critically ill patients—and for those receiving high-risk or vesicant medications, the margin for error is even smaller.
This is where the concept of layering technology into IV therapy protocols becomes not just valuable—but necessary.
Continuous monitoring technology offers something that traditional methods cannot: uninterrupted vigilance. It acts as a second set of eyes, providing real-time insight into what’s happening at the IV site even when clinicians are not physically present. Rather than replacing clinical judgment, it enhances it—offering validation and early warning signals that empower clinicians to act sooner.
And that’s the key: time.
Time to detect a complication before it escalates.
Time to intervene before tissue damage becomes severe.
Time to protect patients from avoidable harm.
Recent clinical research underscores just how critical that time is. A new four-year study published in The BMJ demonstrated that when continuous optical monitoring technology was integrated into neonatal IV protocols, the severity of infiltration injuries dramatically decreased. While the overall number of events remained the same, injuries involving more than 30% of tissue damage dropped from 243 cases to just 54. Moderate severity injuries fell by more than 93%. Median tissue involvement decreased from 15% to just 5%—a clinically meaningful shift that fundamentally alters patient outcomes.
The study further highlighted why this change occurs: continuous monitoring identified infiltration events before clinicians could recognize them at the bedside. Prior research cited in the publication reported sensitivities between 93–100%, with every detection occurring prior to clinical confirmation. This level of reliability is especially critical in populations that cannot verbalize discomfort, such as neonates. Early notifications translate directly into earlier intervention, shorter catheter dwell times, and substantially reduced injury severity—confirming continuous monitoring as a transformative tool in addressing IV therapy’s silent threat.
When clinicians are equipped with continuous monitoring tools, they are no longer relying solely on intermittent checks or patient reported symptoms. They gain actionable data that support faster, more confident decision making. This layered approach to safety acknowledges an important truth: no single method is enough on its own.
By integrating continuous monitoring technology into IV therapy protocols, healthcare systems can move toward a higher standard of care—one that prioritizes early detection, proactive intervention, and can help improve patient outcomes.
Because at the end of the day, preventing harm isn’t just about doing the basics well. It’s about building systems that anticipate risk and respond in real time.
And when it comes to IV therapy, technology gives clinicians the one thing they need most to make a difference: More time.
Learn more about adding IV surveillance technology into your clinical workflows.